



PRESS RELEASE FOR IMMEDIATE USE

Dr. Nancy Zimmerman Accepts Role as Marketing Director, Global Endocrinology for Dechra Pharmaceuticals PLC

July 1, 2018 Overland Park, KS

It is with great pleasure that Dechra announces a new role for Dr. Nancy Zimmerman. As of July 1st, 2018, Dr. Zimmerman will join Dechra's newly formed Global Marketing Team under the direction of Andrea Dodds, the recently appointed Group Marketing Director. Nancy has been the Director of US Marketing since 2012 and has helped the US Commercial Team, led by Mike Eldred and Doug Hubert, to grow the Dechra North American business unit to \$188.5M (fiscal year ending June 30, 2017).

Nancy is ideally suited for this position as she has acquired a diverse medical and business background in her career, including roles in private and corporate veterinary practices and in the pharmaceutical industry. She is a proud graduate of Kansas State University's College of Veterinary Medicine. Nancy has lead the growth of the U.S. Marketing Department from a small group focused on quarterly programs to a team of seven who drive the long term and short term strategy and focus of the U.S. Commercial Team. She has consistently shown a willingness to learn and adapt which has helped the U.S. Team stay ahead of an ever changing marketplace. Her work ethic and skill set will serve her and Dechra well in her new role.



"It was Dechra's endocrinology drugs that first attracted me to join Dechra. I am delighted to join the Global Marketing Team and focus on driving continued success with Dechra's endocrine portfolio," said Dr. Zimmerman. Dechra's global endocrinology portfolio currently includes Vetoryl® Capsules (trilostane), Zycortal® Suspension (desoxycorticosterone pivalate injectable suspension), Felimazole® Coated Tablets (methimazole) and Forthyron® Flavored Tablets (levothyroxine sodium).

Dr. Chris Dujardin, from the Netherlands, is also joining the Global Marketing Team as the new Senior Marketing Manager, Global – Equine. Chris graduated from Utrecht University and became a European Specialist in Veterinary Anesthesia and Analgesia (DipECVAA).

Chris worked for 15 years as an equine veterinarian at university and private practices. He was previously the Equine Business Manager for Dechra EU.

Dechra Veterinary Products, located in Overland Park, Kansas is the U.S. sales and marketing division of Dechra Pharmaceuticals PLC, a UK listed company dedicated to the animal healthcare market. Dechra Veterinary Products' companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management and joint health support. Our brands include VETORYL® Capsules (trilostane), ZYCORTAL® Suspension (desoxycorticosterone pivalate injectable suspension), FELIMAZOLE® (methimazole) Coated Tablets, ANIMAX® OINTMENT (nystatin, neomycin sulfate, thiostrepton, triamcinolone acetonide ointment), VETROPOLYICIN® (bacitracin-neomycin-polymyxin) Veterinary Ophthalmic Ointment and VETROPOLYICIN® HC (bacitracin-neomycin-polymyxin-hydrocortisone acetate 1%) Veterinary Ophthalmic Ointment, VETIVEX® line of parenteral fluids, and PHYCOX® joint health supplements. Dechra also offers a comprehensive line of topical veterinary products including MICONAHEX+Triz®, MALACETIC® and MAL-A-KET™ brands, plus a number of injectable anesthetics, oral anti-infectives and NSAIDs. Dechra's equine portfolio includes OSPHOS® (clodronate injection), Orthokine® vet irap 10 and 60, Osteokine® (PRP), and EQUIDONE® (domperidone) Gel and PHYCOX® EQ joint health supplements. For more information, please visit www.dechra-us.com or call (866) 933-2472